U.S. Patent And Trademark Office Grants Patent for Non-Invasive Blood Glucose Monitoring To Novanex Inc.
North Brunswick, NJ (January 15, 2014) – Novanex Inc. has been granted U.S. patent number 8,676,284 for its noninvasive blood glucose monitoring method by the United States Patent and Trademark Office.
“The addition of this patent to our portfolio reinforces Novanex as a leader and innovator in non-invasive medical device technology, and verifies our novel, proprietary Optimized Metabolic Calorimetry (OMC) technology capabilities,” said Hock S. Tan, Ph.D., chief executive officer of Novanex.
“This patent will be a significant asset to Novanex Inc. as we pursue development and regulatory filing of our first product, which is designed to provide accuracy, comfort, and convenience in non-invasive blood glucose monitoring.”
About Novanex Inc.
Novanex is a U.S.-based medical device company that develops and commercializes innovative technology to monitor, detect and diagnose disease conditions and status. Novanex’s first product focuses on improving the lives of Type 2 Diabetes patients by providing comfort and convenience in personalized non-invasive blood glucose monitoring.
The product uses Novanex’s novel Optimized Metabolic Calorimetry (OMC) technology, based on the principle of metabolic heat conformation. This method uses energy waves emitted by the body— including heat dissipation, blood flow, and local oxygen level— to determine patient glucose levels.
Proof of principle has been established in multi-hospital studies in China, and clinical trials are scheduled for April in the United States.
For additional information, please contact Mark Suseck at 908.310.2613 or email@example.com.